Finance

Beta
Ask
Lists
SRPT:NASDAQ
Sarepta Therapeutics Inc
$17.26
-2.21%
(-0.39) 1D
$17.33
+0.42% (+0.073)
Pre-market
Closed: Jun 23, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for SRPT...
Open
$17.33
High
$17.80
Low
$17.22
Mkt. cap
1.82B
Avg. vol.
3.04M
Volume
801.00
P/E ratio
158.86
52-wk high
$25.32
52-wk low
$10.42
EPS
$0.11
Beta
0.21
Shares outstanding
105.58M
No. of employees
835
Open
$17.33
High
$17.80
Low
$17.22
Mkt. cap
1.82B
Avg. vol.
3.04M
Volume
801.00
P/E ratio
158.86
52-wk high
$25.32
52-wk low
$10.42
EPS
$0.11
Beta
0.21
Shares outstanding
105.58M
No. of employees
835
News stories
From sources across the web
Profile
Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going public the company changed its name from AntiVirals to AVI BioPharma soon with stock symbol AVII and in July 2012 changed name from AVI BioPharma to Sarepta Therapeutics and SRPT respectively. As of 2023, the company has four approved drugs. Wikipedia
About Sarepta Therapeutics Inc
CEODouglas S. Ingram
Employees835
Founded1980
Headquarters-
SectorBiotechnology
Websitesarepta.com
Analyst Ratings
Based on 17 analysts giving stock ratings to SRPT in the past 3 months
Hold
Buy
5
Hold
8
Sell
4
12 month forecast
Based on 17 Wall Street analysts offering 12 month price targets for SRPT in the last 3 months.
Highest
Current $17.26
$38.00 (+120.16%)
Average
$22.81 (+32.16%)
Lowest
$5.00 (-71.03%)
Analyst
Recommendation
Action
Price Target
Projected
Date
Eliana Merle
Barclays
Hold
Maintained
$20.00
+15.9%
06/22/2026
Brian Abrahams
RBC Capital
Hold
Maintained
$19.00
+10.1%
06/18/2026
Anupam Rama
J.P. Morgan
Hold
Maintained
$19.00
+10.1%
05/18/2026
Gavin Clark-Gartner
Evercore ISI
Hold
Maintained
$19.00
+10.1%
05/15/2026
Yun Zhong
Wedbush
Buy
Maintained
$35.00
+102.8%
05/15/2026
Mitchell Kapoor
H.C. Wainwright
Sell
Reiterated
$5.00
-71%
05/08/2026
Kostas Biliouris
Oppenheimer
Buy
Reiterated
$37.00
+114.4%
05/07/2026
Gil Blum
Needham
Sell
Maintained
-
-
05/07/2026
Yanan Zhu
Wells Fargo
Buy
Maintained
$38.00
+120.2%
05/07/2026
Yigal Nochomovitz
Citi
Sell
Maintained
$13.00
-24.7%
05/06/2026
Ritu Baral
TD Cowen
Hold
Maintained
$17.00
-1.5%
05/07/2026
Uy Ear
Mizuho Securities
Buy
Reiterated
$31.00
+79.6%
05/06/2026
Stephen Brozak
WBB Securities
Buy
Maintained
$38.00
+120.2%
03/26/2026
Unknown Analyst
WBB Securities
Buy
Maintained
$38.00
+120.2%
03/26/2026
David Hoang
Deutsche Bank
Sell
Maintained
$14.00
-18.9%
03/26/2026
William Pickering
Bernstein
Hold
Maintained
$20.00
+15.9%
03/25/2026
Michael Ulz
Morgan Stanley
Hold
Reiterated
$25.00
+44.8%
03/26/2026
Joseph Schwartz
Leerink Partners
Hold
Maintained
$15.00
-13.1%
03/25/2026
Kristen Kluska
Cantor Fitzgerald
Hold
Maintained
$21.00
+21.7%
03/16/2026
Biren Amin
Piper Sandler
Hold
Maintained
$16.00
-7.3%
03/11/2026
Unknown Analyst
Guggenheim
Buy
Reiterated
$19.00
+10.1%
03/09/2026
Brian Skorney
Robert W. Baird
Hold
Maintained
$20.00
+15.9%
02/26/2026
Salveen Richter
Goldman Sachs
Hold
Maintained
$17.00
-1.5%
02/25/2026
Sami Corwin
William Blair
Hold
Reiterated
-
-
02/26/2026
Tazeen Ahmad
Bank of America Securities
Sell
Reiterated
$19.00
+10.1%
02/25/2026
Last report
May 6, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
$3.16 / $1.05
+202.07%beat
Revenue / Est. (USD)
730.80M / 477.04M
+53.19%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
611.09M
399.36M
442.93M
730.80M
Cost of goods sold
356.95M
369.66M
724.04M
262.73M
Cost of revenue
356.95M
369.66M
724.04M
262.73M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
137.90M
91.89M
128.30M
108.95M
Operating expense
138.56M
92.57M
128.97M
109.64M
Total operating expenses
495.51M
462.24M
853.02M
372.37M
Operating income
115.58M
-62.88M
-410.08M
358.43M
Other non operating income
-573.00K
-702.00K
-338.00K
1.16M
EBT including unusual items
153.64M
-194.05M
-278.30M
343.17M
EBT excluding unusual items
115.03M
-63.90M
-423.20M
344.24M
Income tax expense
-43.25M
-14.10M
4.55M
12.22M
Effective tax rate
-28.15%
7.27%
-1.64%
3.56%
Other operating expenses
-
-
-
-
Net income
196.89M
-179.95M
-282.85M
330.96M
Net profit margin
32.22%
-45.06%
-63.86%
45.29%
Earnings per share
2.02
-0.13
-3.58
3.16
Interest and investment income
5.25M
7.25M
8.07M
6.36M
Interest expense
-5.23M
-7.56M
-20.84M
-21.71M
Net interest expenses
26.00K
-316.00K
-12.77M
-15.35M
Depreciation and amortization charges
-
-
-
-
EBITDA
126.42M
-44.43M
-404.83M
369.03M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer